<SEC-DOCUMENT>0001576885-23-000058.txt : 20231113
<SEC-HEADER>0001576885-23-000058.hdr.sgml : 20231113
<ACCEPTANCE-DATETIME>20231113072000
ACCESSION NUMBER:		0001576885-23-000058
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20231113
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20231113
DATE AS OF CHANGE:		20231113

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Acumen Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001576885
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				364108129
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40551
		FILM NUMBER:		231395079

	BUSINESS ADDRESS:	
		STREET 1:		427 PARK ST.
		CITY:			CHARLOTTESVILLE
		STATE:			VA
		ZIP:			22902
		BUSINESS PHONE:		925-368-8508

	MAIL ADDRESS:	
		STREET 1:		427 PARK ST.
		CITY:			CHARLOTTESVILLE
		STATE:			VA
		ZIP:			22902
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>abos-20231113.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with the Workiva Platform--><!--Copyright 2023 Workiva--><!--r:ecb67184-129d-4d5e-a955-89c24040a9ed,g:b7360c55-55e1-44bf-9687-2064ea5749e9,d:9307be1f79b4463eb6dba56ff12085dc--><html xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>abos-20231113</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-22">0001576885</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-23">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="abos-20231113.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001576885</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-13</xbrli:startDate><xbrli:endDate>2023-11-13</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i9307be1f79b4463eb6dba56ff12085dc_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">____________________________</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">____________________________</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section&#160;13 or 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported):&#160;<ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">November 13, 2023</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">____________________________</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">Acumen Pharmaceuticals, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of Registrant as Specified in Its Charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">____________________________</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-40551</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">36-4108129</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or Other Jurisdiction</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">of Incorporation)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Commission</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">File Number)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(IRS Employer</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Identification No.)</span></div></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">427 Park St.</ix:nonNumeric>,</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Charlottesville</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-9">Virginia</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">22902</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">434</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">297-1000</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s Telephone Number, Including Area Code)</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Applicable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Former Name or Former Address, if Changed Since Last Report)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">____________________________</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form&#160;8-K&#160;filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:1.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.870%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt:fixed-false" id="f-13">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="f-14">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule&#160;14a-12&#160;under the Exchange Act (17 CFR&#160;240.14a-12)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="f-15">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement&#160;communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR&#160;240.14d-2(b))</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="f-16">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement&#160;communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR&#160;240.13e-4(c))</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.204%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Trading</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Symbol(s)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Name of each exchange </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">on which registered</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock, $0.0001 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">ABOS</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2&#160;of the Securities Exchange Act of 1934&#160;(&#167;240.12b-2&#160;of this chapter).</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="f-20">x</ix:nonNumeric></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityExTransitionPeriod" format="ixt:fixed-false" id="f-21">o</ix:nonNumeric></span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i9307be1f79b4463eb6dba56ff12085dc_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.02&#160;&#160;&#160;&#160;Results of Operations and Financial Condition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 13, 2023, Acumen Pharmaceuticals, Inc. (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) reported financial results and business highlights for the quarter ended September&#160;30, 2023. A copy of this press release (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Earnings Press Release</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) is furnished as Exhibit 99.1 to this Current Report on Form&#160;8-K&#160;(this &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and is incorporated by reference.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information in this Item 2.02 of this Report (including Exhibit 99.1) is being furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exchange Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), or the Exchange Act, except as expressly set forth by specific reference in such a filing.</span></div><div id="i9307be1f79b4463eb6dba56ff12085dc_104"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;7.01&#160;&#160;&#160;&#160;Regulation FD Disclosure.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 13, 2023 the Company announced a credit facility for up to $50 million provided by K2 HealthVentures for capital to support subcutaneous clinical work as well as general corporate purposes. A copy of this press release (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Press Release</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) is furnished as Exhibit 99.2 to this Report and is incorporated by reference.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information in this Item 7.01 of this Report (including Exhibit 99.2), is being furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing. The Company&#8217;s submission of this Report shall not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.</span></div><div id="i9307be1f79b4463eb6dba56ff12085dc_13"></div><div style="-sec-extract:summary;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9.01&#160;&#160;&#160;&#160;Financial Statements and Exhibits.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(d).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:3.28pt">Exhibits</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.727%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="abos-20231113xexx991.htm">Earnings Press Release, dated November 13, 2023</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="abos-20231113xexx992.htm">Press Release, dated November 13, 2023</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i9307be1f79b4463eb6dba56ff12085dc_16"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.627%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Acumen Pharmaceuticals, Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated: November 13, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Matthew Zuga</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Matthew Zuga</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chief Financial Officer and Chief Business Officer</span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>abos-20231113xexx991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i2825ba2d3ba6499a877e308ec6c0c4b8_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div style="margin-top:12pt;text-align:center"><img alt="g410427g05v05a.jpg" src="g410427g05v05a.jpg" style="height:59px;margin-bottom:5pt;vertical-align:text-bottom;width:315px"></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Acumen Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Highlights</font></div><div style="margin-top:6pt;padding-left:18pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:12.53pt">Initiation of a Phase 2 study, ALTITUDE-AD, to investigate ACU193 for the treatment of early Alzheimer&#8217;s disease expected in the first half of 2024, following positive FDA interaction in October 2023</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Announced global collaboration and license agreement with Halozyme for development of a subcutaneous formulation of ACU193</font></div><div style="margin-top:3pt;padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.25pt">Initiation of a Phase 1 study to support a subcutaneous dosing option of ACU193 expected in mid-2024</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Announced a credit facility of up to $50 million from K2 HealthVentures, to provide capital to support subcutaneous clinical work and general corporate purposes</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">CSF biomarker data observed in the Phase 1 INTERCEPT-AD trial support pharmacology of ACU193 and role of amyloid beta oligomers in Alzheimer&#8217;s disease</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Cash, cash equivalents and marketable securities of $282.7 million as of Sept. 30, 2023, expected to support current clinical and operational activities into the second half of 2026</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Company to host conference call and webcast today at 8&#58;00 a.m. ET</font></div><div><font><br></font></div><div style="margin-top:15pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CHARLOTTESVILLE, VA., Nov. 13, 2023 </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#8211;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Acumen Pharmaceuticals, Inc.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;(NASDAQ&#58; ABOS) (&#8220;Acumen&#8221; or the &#8220;Company&#8221;), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (A&#946;Os) for the treatment of Alzheimer&#8217;s disease (AD), today reported financial results for the third quarter of 2023 and provided a business update.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;My excitement for Acumen&#8217;s future is centered on the strength of our ACU193 development strategy for the treatment of early Alzheimer&#8217;s disease, and the deep expertise of our team to execute on that strategy. We continue to make significant operational, regulatory and strategic progress. Following our positive Phase 1 data in the third quarter, we recently had a positive interaction with the FDA and plan to initiate a Phase 2 study in the first half of 2024. On a strategic front, I am excited about our recent collaboration and licensing agreement with Halozyme for the development of a subcutaneous formulation of ACU193, to broaden potential treatment optionality and increase convenience for patients.  To help finance this important workstream, we are pleased to announce today that we have entered into an agreement with K2 HealthVentures for a debt facility of up to $50 million,&#8221; said Daniel O&#8217;Connell, President and Chief Executive Officer of Acumen. &#8220;We have also observed encouraging trends in CSF biomarker data from our Phase 1 study, further solidifying the pharmacology of ACU193. Our talented team is committed to pursuing the full potential of targeting amyloid beta oligomers for this patient population, and </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">I am proud of our progress as we continue to execute at the highest level and work to generate strong and sustainable value, today and into the future.&#8221;</font></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><img alt="g410427g06v12a.jpg" src="g410427g06v12a.jpg" style="height:43px;margin-bottom:5pt;vertical-align:text-bottom;width:226px"></div></div><div style="margin-bottom:8pt;margin-top:18pt"><font style="color:#2f5496;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Recent Highlights and Anticipated Milestones</font></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#2f5496;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ACU193 Clinical Development</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:12.53pt">In October 2023, the Company presented additional detail from first-in-human Phase 1 study of ACU193 for early AD at the Clinical Trials on Alzheimer&#8217;s Disease (CTAD) conference.</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.25pt">Announced dose selection of 50 mg&#47;kg and 35 mg&#47;kg every 4 weeks for ACU193 treatment arms in upcoming placebo-controlled Phase 2 trial based on significant target engagement of A&#946;Os approaching maximal effect.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.25pt">Presented data exploring target engagement modeling of ACU193 to inform dose selection, plus further analyses of dose-related amyloid plaque reduction and clinical characteristics of ARIA-E, confirming proof-of-mechanism for ACU193.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:12.53pt">In October 2023, the Company met with the FDA to discuss the next clinical trial in the development program for ACU193.</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.25pt">The agency indicated they are aligned in principle with the Phase 2&#47;3 study design.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.25pt">In the first half of 2024, the Company expects to initiate a Phase 2 study, ALTITUDE-AD, as the next phase of development for ACU193.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:12.53pt">Today, the Company announced encouraging results from INTERCEPT-AD Phase 1 cerebrospinal fluid (CSF) biomarker data, further supporting the pharmacologic activity of ACU193.</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.25pt">Observed dose dependent trend in the multiple ascending dose cohorts on CSF levels of p-tau181, total tau, neurogranin and A&#946; 42&#47;40 ratio.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.25pt">P-tau181 (p&#61;0.049) and neurogranin (p&#61;0.037) showed statistically significant improvement at 60 mg&#47;kg Q4W as compared to the placebo group after three administrations of ACU193.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.25pt">Nominally significant correlation between target engagement of A&#946;Os and change in neurogranin obsrved across all doses.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.25pt">Trend between target engagement of A&#946;Os and change in p-tau181 observed across all doses.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.25pt">Plasma biomarker analysis in progress.</font></div><div><font><br></font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;We have observed a dose-dependent trend toward drug effect of ACU193 on CSF levels of p</font><font style="color:#0078d4;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">tau181, total tau, neurogranin and the A&#946; 42&#47;40 ratio after only three administrations. The fact that we are observing changes in CSF biomarkers is highly supportive of ACU193&#8217;s downstream pharmacology as determined in our Phase 1 study,&#8221; said Eric Siemers, Chief Medical Officer of Acumen. &#8220;Changes in neurogranin and p-tau181 were statistically significant at the highest dose level studied, and correlated with target engagement of A&#946;Os, consistent with the mechanism of action of ACU193. These data increase our confidence that ACU193 has potential for the treatment of early Alzheimer&#8217;s disease, which we will investigate in our Phase 2 study that is expected to initiate in the first half of 2024.&#8221;</font></div><div style="margin-bottom:8pt;margin-top:12pt"><font style="color:#2f5496;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Corporate Updates</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:12.53pt">In November 2023, announced a global collaboration and licensing agreement with Halozyme for the development of a subcutaneous formulation of ACU193, to potentially offer additional flexibility and convenience for patients and caregivers.</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.25pt">Expect to initiate a Phase 1 trial investigating a subcutaneous dosing option of ACU193 in mid-2024.</font></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><img alt="g410427g06v12a.jpg" src="g410427g06v12a.jpg" style="height:43px;margin-bottom:5pt;vertical-align:text-bottom;width:226px"></div></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:13.8pt">Today, announced a credit facility for up to $50 million provided by K2 HealthVentures, for capital to support subcutaneous clinical work as well as general corporate purposes.</font></div><div style="margin-bottom:8pt;margin-top:18pt"><font style="color:#2f5496;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Third Quarter 2023 Financial Results</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:12.53pt">Cash Balance. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of September 30, 2023, cash, cash equivalents and marketable securities totaled $282.7 million, compared to cash, cash equivalents and marketable securities of $172.2 million as of June 30, 2023.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This increase is due to the net proceeds from the Company&#8217;s public offering of approximately $122 million on July 21, 2023. Altogether, this runway is expected to be sufficient to support current clinical and operational activities into the second half of 2026.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:12.53pt">Research and Development (R&#38;D) Expenses. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">R&#38;D expenses were $11.2 million for the three-month period ended September 30, 2023, compared to $8.3 million for the three-month period ended September 30, 2022. The increase in R&#38;D expenses was primarily due to increased costs related to materials, consulting, personnel and other costs.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:12.53pt">General and Administrative (G&#38;A) Expenses. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">G&#38;A expenses were $4.9 million for the three-month period ended September 30, 2023, compared to $3.1 million for the three-month period ended September 30, 2022. The increase in G&#38;A expenses was primarily due to increased costs related to personnel, consulting and legal&#47;patent services.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:12.53pt">Loss from Operations.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Losses from operations were $16.0 million for the three-month period ended September 30, 2023, compared to $11.4 million for the three-month period ended September 30, 2022. This increase was due to the increased R&#38;D and G&#38;A expenses over the prior year period.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:12.53pt">Net Loss. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net loss was $13.0 million for the three-month period ended September 30, 2023, compared to $10.7 million for the three-month period ended September 30, 2022.</font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Conference Call Details</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Acumen will host a conference call and live audio webcast today, Nov. 13, 2023, at 8&#58;00 a.m. ET.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including PIN. Please register at least one day in advance.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The webcast audio will be available via this&#8239;link.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">An archived version of the webcast will be available for at least 30 days in the Investors section of the Company's website at www.acumenpharm.com.</font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About ACU193</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ACU193 is a humanized monoclonal antibody (mAb) discovered and developed based on its selectivity for soluble A&#946;Os, which Acumen believes are the most toxic and pathogenic form of A&#946;, relative to A&#946; monomers and amyloid plaques. Soluble A&#946;Os have been observed to be potent neurotoxins that bind to neurons, inhibit synaptic function and induce neurodegeneration. By selectively targeting toxic soluble A&#946;Os, ACU193 aims to directly address a growing body of evidence indicating that soluble A&#946;Os are a primary underlying cause of the neurodegenerative process in Alzheimer&#8217;s disease.</font></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><img alt="g410427g06v12a.jpg" src="g410427g06v12a.jpg" style="height:43px;margin-bottom:5pt;vertical-align:text-bottom;width:226px"></div></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">ACU193 has been granted Fast Track designation for the treatment of early Alzheimer&#8217;s disease by the U.S. Food and Drug Administration.</font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About INTERCEPT-AD</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">INTERCEPT-AD was a Phase 1, U.S.-based, multi-center, randomized, double-blind, placebo-controlled clinical trial evaluating the safety and tolerability, and establishing clinical proof of mechanism, of ACU193 in patients with early Alzheimer&#8217;s disease (AD). Sixty-five individuals with early AD (mild cognitive impairment or mild dementia due to AD) enrolled in this first-in-human study of ACU193. The INTERCEPT-AD study consisted of single-ascending-dose (SAD) and multiple-ascending-dose (MAD) cohorts and was designed to evaluate the safety, tolerability, pharmacokinetics (PK), and target engagement of intravenous doses of ACU193. More information can be found on www.clinicaltrials.gov, NCT identifier NCT04931459.</font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About Acumen Pharmaceuticals, Inc.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Acumen, headquartered in Charlottesville, VA, with </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">offices in </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Indianapolis, IN,</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Newton, MA, is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (A&#946;Os) for the treatment of Alzheimer&#8217;s disease (AD). Acumen&#8217;s scientific founders pioneered research on A&#946;Os, which a growing body of evidence indicates are early and persistent triggers of Alzheimer&#8217;s disease pathology. Acumen is currently focused on advancing its investigational product candidate, ACU193, a humanized monoclonal antibody that selectively targets toxic soluble A&#946;Os, following positive topline results in INTERCEPT-AD, a Phase 1 clinical trial involving early Alzheimer&#8217;s disease patients. For more information, visit www.acumenpharm.com.</font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Forward-Looking Statements</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Any statement describing Acumen&#8217;s goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Words such as &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;seeks,&#8221; &#8220;aims,&#8221; &#8220;plans,&#8221; &#8220;potential,&#8221; &#8220;will,&#8221; &#8220;milestone&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements include statements concerning Acumen&#8217;s business, and Acumen&#8217;s ability to achieve its strategic and financial goals, including its projected use of cash, cash equivalents and marketable securities and the expected sufficiency of its cash resources into the second half of 2026, the therapeutic potential of Acumen&#8217;s product candidate, ACU193, including against other antibodies, the anticipated timeline for initiating a Phase 2 clinical trial of ACU193 and a Phase 1 trial to support a subcutaneous dosing option of ACU 193, and the expected use of proceeds from a credit facility. These statements are based upon the current beliefs and expectations of Acumen management, and are subject to certain factors, risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing safe and effective human therapeutics. Such risks may be amplified by the impacts of geopolitical events and macroeconomic conditions, such as rising inflation and interest rates, supply disruptions and uncertainty of credit and financial markets. These and other risks concerning Acumen&#8217;s programs are described in additional detail in Acumen&#8217;s filings with the Securities and Exchange Commission (&#8220;SEC&#8221;), including in Acumen&#8217;s most recent Annual Report on Form 10-K, and in subsequent filings with the SEC. Copies of these and other documents are available from Acumen. Additional information will be made available in other filings that Acumen makes from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and Acumen </font></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><img alt="g410427g06v12a.jpg" src="g410427g06v12a.jpg" style="height:43px;margin-bottom:5pt;vertical-align:text-bottom;width:226px"></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">expressly disclaims any obligation to update or revise any forward-looking statement, except as otherwise required by law, whether, as a result of new information, future events or otherwise.</font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONTACTS&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Investors&#58;</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Alex Braun</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">abraun&#64;acumenpharm.com</font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Media&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AcumenPR&#64;westwicke.com</font></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><div id="i2825ba2d3ba6499a877e308ec6c0c4b8_4"></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div style="text-align:center"><img alt="g410427g06v12a.jpg" src="g410427g06v12a.jpg" style="height:43px;margin-bottom:5pt;vertical-align:text-bottom;width:226px"></div></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Acumen Pharmaceuticals, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Condensed Balance Sheets</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:67.033%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.529%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.532%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">September 30, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">December 31, 2022</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(unaudited) </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ASSETS</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Current assets</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">94,917&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">130,101&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Marketable securities, short-term</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">120,517&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">47,504&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3,164&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,724&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total current assets</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">218,598&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">180,329&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Marketable securities, long-term</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">67,270&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15,837&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Restricted cash</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">189&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Property and equipment, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">123&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">165&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Right-of-use asset</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">105&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">189&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">151&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total assets</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">286,371&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">196,587&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</font></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Current liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Accounts payable</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,362&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,640&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Accrued clinical trial expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,566&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,717&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3,168&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3,350&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Operating lease liability</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">105&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total current liabilities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6,098&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7,812&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total liabilities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6,098&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7,812&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Commitments and contingencies</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Stockholders&#8217; equity</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Preferred stock, $0.0001 par value&#59; 10,000,000 shares authorized and no shares issued and outstanding as of September 30, 2023 and December 31, 2022</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Common stock, $0.0001 par value&#59; 300,000,000 shares authorized as of September 30, 2023 and December 31, 2022&#59; 57,910,461 and 41,025,062 shares issued and outstanding as of September 30, 2023 and December 31, 2022</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Additional paid-in capital</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">487,077&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">359,949&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Accumulated deficit</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(206,301)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(170,427)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(509)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(751)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">280,273&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">188,775&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">286,371&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">196,587&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div><div id="i2825ba2d3ba6499a877e308ec6c0c4b8_7"></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div style="text-align:center"><img alt="g410427g06v12a.jpg" src="g410427g06v12a.jpg" style="height:43px;margin-bottom:5pt;vertical-align:text-bottom;width:226px"></div></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Acumen Pharmaceuticals, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Condensed Statements of Operations and Comprehensive Loss</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:46.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.646%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.646%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.646%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.652%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Three Months Ended September 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2022</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Operating expenses</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Research and development</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11,179&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8,309&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">29,025&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">21,615&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">General and administrative</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4,860&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3,062&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13,627&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9,374&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16,039&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11,371&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">42,652&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">30,989&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Loss from operations</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(16,039)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(11,371)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(42,652)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(30,989)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other income (expense)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Interest income, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3,124&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">663&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6,840&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other expense, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(42)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(62)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total other income</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3,082&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">661&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6,778&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">999&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net loss</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(12,957)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(10,710)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(35,874)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(29,990)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other comprehensive gain (loss)</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Unrealized gain (loss) on marketable securities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">137&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">242&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(734)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Comprehensive loss</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(12,820)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(10,710)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(35,632)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(30,724)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net loss per common share, basic and diluted</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.24)</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.26)</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.79)</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.74)</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Weighted-average shares outstanding, basic and diluted</font></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">54,229,630</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">40,502,860</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">45,474,953</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">40,491,181</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></div></div><div id="i2825ba2d3ba6499a877e308ec6c0c4b8_10"></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div style="text-align:center"><img alt="g410427g06v12a.jpg" src="g410427g06v12a.jpg" style="height:43px;margin-bottom:5pt;vertical-align:text-bottom;width:226px"></div></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Acumen Pharmaceuticals, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Condensed Statements of Cash Flows</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(in thousands)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.506%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.295%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2022</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Cash flows from operating activities</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net loss</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(35,874)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(29,990)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Depreciation</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">42&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">20&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Stock-based compensation expense</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4,511&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,173&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Amortization of premiums and accretion of discounts on marketable securities, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1,344)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">575&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Amortization of right-of-use asset</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">103&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(436)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,058&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(38)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(78)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Accounts payable</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(278)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">996&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Accrued clinical trial expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1,151)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,358&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Operating lease liability</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(103)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(100)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(182)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1,062)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net cash used in operating activities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(34,750)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(23,950)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Cash flows from investing activities</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Purchases of marketable securities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(178,857)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(12,129)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Proceeds from maturities and sales of marketable securities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">55,997&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">71,860&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Proceeds from sale of property and equipment</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Purchases of property and equipment</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(7)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(126)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(122,864)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">59,605&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Cash flows from financing activities</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock, net of issuance costs</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">122,294&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">325&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Payments for deferred offering costs</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(296)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">122,619&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(277)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net change in cash and cash equivalents and restricted cash</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(34,995)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">35,378&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash and cash equivalents and restricted cash at the beginning of the period</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">130,101&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">122,162&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash and cash equivalents and restricted cash at the end of the period</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">95,106&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">157,540&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>abos-20231113xexx992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ie82d2ca470554e16a17d4f85df0ac9bf_1"></div><div style="min-height:63pt;width:100%"><div style="margin-top:12pt;text-align:right"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 99.2</font></div><div style="text-align:center"><img alt="image_0.jpg" src="image_0.jpg" style="height:38px;margin-bottom:5pt;vertical-align:text-bottom;width:196px"></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Acumen Pharmaceuticals Secures $50.0 Million Credit Facility with K2 HealthVentures</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-top:6pt;padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.15pt">Provides additional capital to support development of a subcutaneous formulation of ACU193 and general corporate purposes</font></div><div style="padding-left:36pt"><font><br></font></div><div style="margin-bottom:6pt;padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:14.15pt">$30 million drawn down at loan closing</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Charlottesville, VA., Nov. 13, 2023</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> &#8211; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Acumen Pharmaceuticals, Inc.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (NASDAQ&#58; ABOS) (&#8220;Acumen&#8221; or the &#8220;Company&#8221;), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (&#8220;A&#946;Os&#8221;) for the treatment of Alzheimer&#8217;s disease (&#8220;AD&#8221;), today announced that it has entered into a senior secured loan and security agreement (the &#8220;Loan Agreement&#8221;) with K2 HealthVentures, a healthcare-focused specialty finance company. </font></div><div style="margin-bottom:5pt;margin-top:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;We are pleased to announce this agreement with K2 HealthVentures, a life sciences investment firm known for strategic investments in promising healthcare companies,&#8221; said Daniel O&#8217;Connell, President and Chief Executive Officer of Acumen.&#160; &#8220;This financing provides us with additional operational flexibility during a period when we are laser-focused on execution. In particular, the funding will support our recently announced development program for a subcutaneous form of ACU193, including a Phase 1 study which we expect to initiate in mid-2024.&#8221;</font></div><div style="margin-bottom:5pt;margin-top:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;We are excited to partner with Acumen on this financing to support management&#8217;s vision of developing a potential best-in-class treatment for early Alzheimer&#8217;s Disease,&#8221; said Nimesh Shah, Managing Director at K2 HealthVentures. &#8220;This financing follows our strategy of partnering with pioneering life science companies developing treatments that have the potential to transform lives.&#8221;</font></div><div style="margin-bottom:5pt;margin-top:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Loan Agreement provides up to $50.0 million principal in term loans (the &#8220;Term Loan&#8221;) consisting of a first tranche of $30.0 million, which was funded at closing, and a second tranche of up to $20.0 million which may be funded in installments upon the Company&#8217;s request, subject to review by the lenders of certain information from the Company and discretionary approval from the lenders. The Term Loan matures on November 1, 2027 and may be extended to November 1, 2028 if the Company achieves certain financing milestones. Additional details regarding the Loan Agreement will be included in the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023.</font></div><div style="margin-bottom:14pt;margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About Acumen Pharmaceuticals, Inc.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Acumen, headquartered in Charlottesville, VA, with </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">additional offices in Indianapolis, IN and Newton, MA</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (A&#946;Os) for the treatment of Alzheimer&#8217;s disease (AD). Acumen&#8217;s scientific founders pioneered research on A&#946;Os, which a growing body of evidence indicates are early and persistent triggers of Alzheimer&#8217;s disease pathology. Acumen is currently focused on advancing its investigational product candidate, ACU193, a humanized monoclonal antibody that selectively targets toxic soluble A&#946;Os, following positive topline results in INTERCEPT-AD, a Phase 1 clinical trial involving early Alzheimer&#8217;s disease patients. For more information, visit </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">www.acumenpharm.com.</font></div><div style="margin-top:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div style="margin-top:12pt;text-align:right"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="text-align:center"><img alt="image_0.jpg" src="image_0.jpg" style="height:38px;margin-bottom:5pt;vertical-align:text-bottom;width:196px"></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Acumen Forward-Looking Statement</font></div><div style="margin-top:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995.&#160; Any statement describing Acumen&#8217;s goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement.&#160;Words such as &#8220;may,&#8221; &#8220;expects,&#8221; &#8220;provided&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements include statements concerning Acumen&#8217;s plans to initiate a Phase 1 study for its subcutaneous development program for ACU193 in mid-2024, Acumen&#8217;s ability to receive a second tranche of up to $20.0 million under the Loan Agreement and the potential for the maturity date of the Loan Agreement to be extended. These statements are based upon the current beliefs and expectations of Acumen management, and are subject to certain factors, risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing safe and effective human therapeutics. Such risks may be amplified by the impacts of geopolitical events and macroeconomic conditions, such as rising inflation and interest rates, supply disruptions and uncertainty of credit and financial markets. These and other risks concerning Acumen&#8217;s programs are described in additional detail in Acumen&#8217;s filings with the Securities and Exchange Commission (&#8220;SEC&#8221;), including in Acumen&#8217;s most recent Annual Report on Form 10-K, and in subsequent filings with the SEC. Copies of these and other documents are available from Acumen.&#160;Additional information will be made available in other filings that Acumen makes from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and Acumen expressly disclaims any obligation to update or revise any forward-looking statement, except as otherwise required by law, whether, as a result of new information, future events or otherwise.</font></div><div><font><br></font></div><div style="margin-top:24pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONTACTS&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Investors&#58; </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Alex Braun</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">abraun&#64;acumenpharm.com</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Media&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">AcumenPR&#64;westwicke.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>abos-20231113.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:ecb67184-129d-4d5e-a955-89c24040a9ed,g:b7360c55-55e1-44bf-9687-2064ea5749e9-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:abos="http://acumenpharm.com/20231113" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://acumenpharm.com/20231113">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="abos-20231113_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="abos-20231113_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://acumenpharm.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>abos-20231113_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:ecb67184-129d-4d5e-a955-89c24040a9ed,g:b7360c55-55e1-44bf-9687-2064ea5749e9-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_SecurityExchangeName_0c9ea4ae-6d3f-48c6-9a2e-d2bd705db2ec_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_aa4332c5-42f8-4e14-aa8a-3c0f4f0df486_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_89ade55a-07d5-422a-b35d-474e431b17c5_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_7a665709-eca5-46ec-8084-b3d4621ecf7b_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_7078adc3-5a41-4835-8c7b-2521041b6cf9_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_05c39320-067c-4c04-9bbd-700d3e1f775a_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_ed9858d6-4ae7-4bcf-b4c2-c04857b510a3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_db83779e-0646-4ec8-a019-cce7cf969cb3_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_b8382e9e-1fb9-49ee-ac54-faa76366a473_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_a09a730a-929c-41f2-bd21-c2b826ac4b91_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_485495cd-9f94-4e6f-a35d-fecf2a716147_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_60625b27-a33a-4145-badd-e8c1728dbdd0_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_f877f110-10cf-44d9-abf7-a7ac247e0aee_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_bb62d59a-3e48-4303-ad25-381ec4595f96_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_10e5a10a-f69a-48ab-bd9f-3034a63e649e_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_79cb6a96-24fa-4d5f-b6c8-aea365cc7769_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_1ff84ab2-b153-4a48-911e-4eae3d4c815f_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_a70ae9de-f045-45be-9a3e-cae460eb8b9b_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_f2489502-46ec-46c3-98e4-85256c1c2c47_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_a115ce40-8509-445c-89dd-c5223ab44935_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_028fe69e-94f2-4a80-80ac-95d1dc3b5abe_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_755b6d8c-0d8e-4cb0-af69-3166d79a4b32_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_8e02e83a-6b61-452d-aa4c-b44a8ec21404_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>abos-20231113_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:ecb67184-129d-4d5e-a955-89c24040a9ed,g:b7360c55-55e1-44bf-9687-2064ea5749e9-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://acumenpharm.com/role/Cover" xlink:type="simple" xlink:href="abos-20231113.xsd#Cover"/>
  <link:presentationLink xlink:role="http://acumenpharm.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_79895fd3-779c-4538-a2df-04ea7f0b12ac" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_b80c68f6-b573-4db6-81f6-fab435e26eff" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_79895fd3-779c-4538-a2df-04ea7f0b12ac" xlink:to="loc_dei_DocumentType_b80c68f6-b573-4db6-81f6-fab435e26eff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_cca1cd0b-a540-451c-9b82-3f12ccca2a88" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_79895fd3-779c-4538-a2df-04ea7f0b12ac" xlink:to="loc_dei_DocumentPeriodEndDate_cca1cd0b-a540-451c-9b82-3f12ccca2a88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_1d903553-32c1-4810-8eb4-411c61c5af6c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_79895fd3-779c-4538-a2df-04ea7f0b12ac" xlink:to="loc_dei_EntityRegistrantName_1d903553-32c1-4810-8eb4-411c61c5af6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_6e3d9008-71e4-41e7-aaae-4a48811c0db6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_79895fd3-779c-4538-a2df-04ea7f0b12ac" xlink:to="loc_dei_EntityIncorporationStateCountryCode_6e3d9008-71e4-41e7-aaae-4a48811c0db6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_90bb369b-7f8e-4731-843c-cb535f015678" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_79895fd3-779c-4538-a2df-04ea7f0b12ac" xlink:to="loc_dei_EntityFileNumber_90bb369b-7f8e-4731-843c-cb535f015678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_367fcb3e-cf82-4088-8bdf-a3063e17d458" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_79895fd3-779c-4538-a2df-04ea7f0b12ac" xlink:to="loc_dei_EntityTaxIdentificationNumber_367fcb3e-cf82-4088-8bdf-a3063e17d458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_0544b8cd-d6b7-4e2f-a827-b139d7c570b5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_79895fd3-779c-4538-a2df-04ea7f0b12ac" xlink:to="loc_dei_EntityAddressAddressLine1_0544b8cd-d6b7-4e2f-a827-b139d7c570b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_4fe895c4-a59c-4db8-9506-350af795db0b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_79895fd3-779c-4538-a2df-04ea7f0b12ac" xlink:to="loc_dei_EntityAddressCityOrTown_4fe895c4-a59c-4db8-9506-350af795db0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_edd1e96a-7d9f-42c1-9d3a-d0dbaee7fa59" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_79895fd3-779c-4538-a2df-04ea7f0b12ac" xlink:to="loc_dei_EntityAddressStateOrProvince_edd1e96a-7d9f-42c1-9d3a-d0dbaee7fa59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_30ab3ec7-fc8a-4ccd-aa7e-176404411bad" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_79895fd3-779c-4538-a2df-04ea7f0b12ac" xlink:to="loc_dei_EntityAddressPostalZipCode_30ab3ec7-fc8a-4ccd-aa7e-176404411bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_06d1bfe6-ed6f-4d97-b31b-d1035518fb66" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_79895fd3-779c-4538-a2df-04ea7f0b12ac" xlink:to="loc_dei_CityAreaCode_06d1bfe6-ed6f-4d97-b31b-d1035518fb66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_86fed466-77ea-4b2a-930a-61709559225a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_79895fd3-779c-4538-a2df-04ea7f0b12ac" xlink:to="loc_dei_LocalPhoneNumber_86fed466-77ea-4b2a-930a-61709559225a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_6c3c1570-48b9-429a-b60c-e5a0a60aa57c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_79895fd3-779c-4538-a2df-04ea7f0b12ac" xlink:to="loc_dei_WrittenCommunications_6c3c1570-48b9-429a-b60c-e5a0a60aa57c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_ac8210f9-f991-46a3-85bf-c2e94bff14b6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_79895fd3-779c-4538-a2df-04ea7f0b12ac" xlink:to="loc_dei_SolicitingMaterial_ac8210f9-f991-46a3-85bf-c2e94bff14b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_e5880e3c-073a-41f2-9785-3b5903a037c1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_79895fd3-779c-4538-a2df-04ea7f0b12ac" xlink:to="loc_dei_PreCommencementTenderOffer_e5880e3c-073a-41f2-9785-3b5903a037c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_a7b77ab8-0e9b-49a3-86d0-5b4d8a28225e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_79895fd3-779c-4538-a2df-04ea7f0b12ac" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_a7b77ab8-0e9b-49a3-86d0-5b4d8a28225e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_3de0a80d-aae3-47ea-9311-c08510cdfdb0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_79895fd3-779c-4538-a2df-04ea7f0b12ac" xlink:to="loc_dei_Security12bTitle_3de0a80d-aae3-47ea-9311-c08510cdfdb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_ae69ffe9-2013-47cf-9d7d-ca38bb66bcc3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_79895fd3-779c-4538-a2df-04ea7f0b12ac" xlink:to="loc_dei_TradingSymbol_ae69ffe9-2013-47cf-9d7d-ca38bb66bcc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_bb28d1e1-5c73-4790-a142-abbb8dcd32c6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_79895fd3-779c-4538-a2df-04ea7f0b12ac" xlink:to="loc_dei_SecurityExchangeName_bb28d1e1-5c73-4790-a142-abbb8dcd32c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_832a0181-579c-4013-aa29-a7346c15cf61" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_79895fd3-779c-4538-a2df-04ea7f0b12ac" xlink:to="loc_dei_EntityEmergingGrowthCompany_832a0181-579c-4013-aa29-a7346c15cf61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_f0139db2-5e0c-467c-8ed2-e333de3125a2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_79895fd3-779c-4538-a2df-04ea7f0b12ac" xlink:to="loc_dei_EntityExTransitionPeriod_f0139db2-5e0c-467c-8ed2-e333de3125a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_ba2366fa-e58e-42a4-9348-94b97a1c4df1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_79895fd3-779c-4538-a2df-04ea7f0b12ac" xlink:to="loc_dei_EntityCentralIndexKey_ba2366fa-e58e-42a4-9348-94b97a1c4df1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_401119d0-ddba-45fa-8197-9d878c09076a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_79895fd3-779c-4538-a2df-04ea7f0b12ac" xlink:to="loc_dei_AmendmentFlag_401119d0-ddba-45fa-8197-9d878c09076a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g410427g05v05a.jpg
<TEXT>
begin 644 g410427g05v05a.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 B17AI9@  34T *@    @  0$2  ,
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M# P,# P,# P,_\  $0@ 4 &D P$B  (1 0,1 ?_$ !\   $% 0$! 0$!
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MGS.VESR\OS:GBY.--/0]3$RERNY=P&2,\BG YK\F_P#@K/\ \%5?&'_!./\
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MX+G?'CQ9^SA_P3N\7>*O!>L2Z'K]C+:K!=QHKL@:95;A@1R">U>A4RNI#&K
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M>,;N\@CUJ.QDCT6U?YFN;MAMC&WNH=ESZ"OH+J*_!;_@[4^,^H7_ .T-\.?
M,=VRZ;I^D-JLT"G =Y9&4;O7_5#%?,</Y>L;CH49?#N_1'M9IBOJ^&E46_0_
M,/XO_&7QQ^UK\7I/$GBW4+_Q3XNUJ588SMW2,6.$BC0#CL  *_5W_@EM_P &
MTMO\2_ .G^,_CY'J5DNIK]HM?#]O=>4Z1'&SSROS*Q'. W&1GFOFO_@W)_9'
MM?VDOV_K/6]<T];WP]X%M7U-5D_U;W0PL8/KM+!A[BOZ6HHEBB554*JC  '
M%?9\59]4PDE@<'[MDKM=/)=CYW(\KC77UO$>]=Z7/E_P?_P1F_9F\#Z/'8V?
MPE\,R11ILW7,37$A^K.22?QK#\=_\$(?V6?B%#*MU\+=+M9) 0'LKB:V*$]Q
ML<5]>E<BEQ7P*S/&*7,JLK_XG_F?5/!T&N5P5O1'P=^PG_P1$\,_\$[OVQ[K
MQ]X#UC4)_#NI:+-I]Q8ZA-YDD,C.C+L./N@ CDYKZ@_;6./V/_B;_P!BS?\
M_HAZ]1Q7EW[;?'['OQ._[%F__P#1#U4L96Q.)A4KRYGHK^C)CAZ=&C*%-66O
MY'\=EV<V%Y_UTD_]"-?UX?\ !,H?\:__ (0_]BO9?^BEK^0^[/\ H5Y_UUD_
M]"-?UY?\$SAC]@#X0_\ 8K6/_HI:_0.//]VI>K_(^6X8_CU?ZZGN5<S\93CX
M4>(_^P;<?^BVKIJYCXTG;\)?$G_8-N/_ $6U?F5/XUZGV,OA9_&EKK?\3O5/
M^ON7_P!#-?UW_P#!/#_DQGX4_P#8LV7_ **%?R(:[_R&M4_Z^Y?_ $,U_7A_
MP3R&/V&_A3_V+-G_ .BA7Z7QY_N]'U?Y'Q?"O\6H?B3_ ,'8XS^WYX+![^$(
MO_2B>O0/^#9?]K;4/A!X-^(UGXH\0WD?PY\'V$VJM:LOF1V(!CWNH +  $G
MXZ\5Y_\ \'8PS^W]X+_[%&+_ -*)ZXC_ ((Y(K?LH_M-,PR/^$-OU/TV)75&
MC&KP_3A/9I?C(S]I*&;3E'S/Z*?@_P#&#P[\>OAII'B_PGJEOK'A_7;=;FSN
MH3E94/Z@CH0>01BNH[5_-S_P0Q_X+8:E^Q-KFE_#_P"(6K22?".</Y#F$S2:
M5,YR,$?-Y9.>.<%J_?SXI?M<?#WX-_ 5?B7X@\26%EX-FMH[J#4-^Z.X20;D
MV8^\6&,8KX/.,CKX'$>RLVI/W6NOEZ]T?58',J6)I>T3LUOY$W[3O[47@O\
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M>NN_X-;? FE_$[7_ (H>'M<M([[2-9TR:TN[=_NRQOY:LI^HKD?^#L;_ )2
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M-J$BOD.Z\?*-O0YSNKB_^#HH>7_P43TJ->$B\+6R(/[JB67 %?T3>$/">F^
M_"]AHVCV5MIVEZ9 EO:VUO&(XX8U "JJC@  5_.Q_P '19S_ ,%&]/\ ^Q9M
M_P#T;+7/D.;5<PSCVM391=EV7];FN;8&GA<N]G#NKON?7?\ P:+?\FZ_$C_L
M._\ LHKZ*_X.1#_QJQ\:_P#7:T_]*$KYU_X-%!_QCC\1_P#L/'_T$5]$?\'(
MYQ_P2R\:?]=[3_TH2O+QG_)1K_'']#NA_P BE_X6?@;_ ,$PSG_@H!\'?^QD
MMOYU]+?\%*?^"2WQV^+?[>'Q.\2Z%\-;O5-'UC6&GM;I9H0)DVCGEL_G7S3_
M ,$P5W?\% /@[_V,=M_.OZY#!&S<QJ>_(KZ/B3.:N78V%2DD[Q:U]3Q\DR^&
M+PTH3;5GT/Y/S_P11_:,'_-)[W_P(@_^+K]IO^#:K]E7QQ^R9^R3XJT/QYX<
MF\-ZE>>(I+J*"1T;?&44!LJ2.U?HU]EC_P"><?\ WR*<J+&/E55^@Q7R6;<5
M8C'X?ZO4BDKIZ7Z'T&!R:GA:GM(R;]2CXKX\*ZG_ ->LO_H!K^-3XO'/Q3\4
M_P#84N/_ $,U_97XL_Y%;4_^O27_ - -?QI_%PY^*?BC_L*7'_H9KWO#_>O_
M -N_J>/Q5_RZ^?Z']&O[#G[('A7]N#_@B;X1\ >*K2&:UU2PF^S7#)N>PG$K
ME)DZ'*GG@C(XK\+?^"A/[ WC7_@FC^T9+X5UJ::2&)Q>Z%KMJ65;F+.8W!ZI
M(I&"/5>_6OZ*_P#@B8-O_!-+X:_]>TO_ *->O1/V\/V(/"/[>?P UKP3XGL;
M-I+V$FPU!X0TVFW ^Y*AX(P>P(R,CO7FX'B">7YA5IU-:<I.Z[:[K]5U.W$Y
M3'%X2G*&DU%6?RV/SI_X-_?^"U]U\:;_ $7X%?$F2\N?%*VK1Z)K,C>8-2"9
M/E2=PX3N<YVGG-?D/_P414C]OSXU#^+_ (3#4_P_TEZ^V/V)O^"<7CS_ ()R
M_P#!;3X4^'?%T27FE7E_>#2-8A/[K4(UMI#DCJK $9![YQFOBG_@HP-G_!0'
MXV?]CCJ9_P#)B2OL,JP^%AF-2IA/AG!2TVOS/;MML>!F52N\'".(^*,FOP1^
MW'_!OX,?\$Z-%_["4_\ Z*AHIW_!O^,?\$Z-$_[",W_HJ&BOSW./]]J_XF?5
M8#_=X>B/TG\9^+[+P/X=NM2OIEB@MHV?E@-V!G ]Z^!?CI\9KSXW^-I-3F\V
M&SC'EVMLS96)1W^IZU]<_M%?LX7/Q]FL4DUZ33+&Q!;R$AW>8Q[GYATKS5O^
M";\8SCQ5)[?Z)_\ 95W</XC+L)'VU:?[Q^3T7W=3YWB?"YKC9^PH4_W:\U[S
M^;V1\F>+/$4?AC1WN&VM)]V-,\L37D6J:I/K5_)<3L7DD/4GI["OMKQ!_P $
MDKOQ%J#W,WCKYF/"_8/E4?\ ?=44_P""/$R,#_PG"\'/_(/_ /LZ^[PO%&3T
MEK5U_P ,O\CX_P#U3S7_ )]?C'_,_-CXZ>*?[%N)/+.)VPB<\CCDUXTQ9G9F
M^8MR2>YK]0O&W_!OY?>-?$=QJ$OQ.\KSC\L8TK(0?7S*R?\ B'0N /\ DJ'_
M )2?_MM<&8<68'$37+4]U*RT?W[=3[+(>'ZF H-2C[\G>3T^2^7^9^9]]?PZ
M;927-S*D,,*%W9C@ "OD_P",GQ<D^(_B"22UC:SL%^0(I_UW/WFK]IOC+_P:
M\ZM\6/L\*_&8:?9V^28ET0MYK'N?WPK@S_P:!W7_ $6X?^"#_P"W487B+*H>
M].KK_AEI^!IF6!QU7]W3A[OJM?Q/QA[T5^TB?\&@!V_-\<),_P#8 _\ MU._
MXA ?^JWR?^"#_P"W5V_ZW95_S]_\E?\ D>3_ *OX[^3\5_F?BPZ[E-?J/_P3
M=2]_:0^$W@WP]IK--JR$6,G\3!4)'/?[JFO8/^(0'_JM\G_@@_\ MU?67_!)
MG_@A\/\ @F5\3-<\07'Q ;QHFJ6H@M[=]-^S"T;()<'S&Y/(Z#K7YEXIX7+.
M)\KIX:G5]^G4C):-76TE>R^R[^J1U8/(<6JJ56-H]=5M]Y]O?"SP#9_##X?Z
M7HMC#'##I]LD7R+MW$* 2?>O#?\ @JU^V=8?L1?L<^)O$]Q.8=2OK:6PTG:P
M#-=/&Q3K]*^E",U\._\ !8#_ ()#ZI_P51E\'V__  L3_A#M)\*>=+]E73C=
M?:YI-F'8^8H^4+QQ_$:\_)Z.%A7ITZ[Y:<?+HMEI]Q]KBE4C0<:"UM9'\R.M
MZ[?>)=6O-2U*ZFO+Z^E:>:65B[R,QSR3Z=/PK^B/_@V$_94_X4I^PS<>,M4L
M5M]?\?:C)=%WC*S);1@1QQG/8,KL/]ZO /"G_!HLVB^+]*O+WXR?;M/L[R*>
MYMQH6UIXU8%DSYQQD#&<'K7[->$?"UGX*\,V.E6,,<%KI\"01HBA5 4 =!ZU
M]KQ5Q%AL3AHX;!RNF]=&M%LM4OZ1\]D>45J-9U\0K/I\_0D?PUILKLS:?8LS
M'))@4DG\J0^%M+Q_R#K#_P !T_PJ_0>:_/\ F9]79'$_%_X#^&/C1\-]7\,Z
MSH>EWEAJMNT+QR6ZE2<?*3QV.#^%?R._M6? '5/V8?VC?&/@?5(9(VT/4YX+
M9V0JL\(=@CKG^$XZU_8P1D5^>?\ P5O_ ."$5K_P4O\ B]H'C+3O&D?@O4M-
MLFL;L?V:+D7:[@R'AUP1\W7/6OK>$\\A@JTH8AVA);ZNS7^9X6?99+%4E*DO
M>1\5_P#!K1^W2O@'XA:W\%==OIY(?$LPO=#224;(I C&11GV51@5^VGQQ^#F
MB_M ?"/Q!X-\1V4%_H_B"REL[B&5=RX=2,_49R".17Y,_ +_ (-9/$'[/OQR
M\)^.M+^-<+ZAX4U.#48H_P"PR@F\MPQC)$W1@,'ZU^QULCI;QB1E:15 9@,
MG')KGXEQ&$JXQ8K SO?5Z-6:]4C;)Z->&']CB8[?/0_D]_X*6?\ !,KQI_P3
ME^,=WHNK6MWJWA.Y;S-/UQ+=A;.'R1$S= PZ8R>!6E^P+_P5Y^,'[ NJ6=GH
M>N7FM>"[<LS>'KJ;,'S<G8S!MG/.%'K7]17QD^"WAKX^_#W4?"_BS2;'6=&U
M2+RYK>YA613W! (Z@\BORC_:7_X--/#/C+Q5J&K?#CXAWGAB*[D,J:;>V(N(
M(B>JJ59=J^@QQ7TF XKP>+H?5\TCKWM=/STV9X^*R/$4*OML"_D0^$O^#NKP
M8^F1?V[\,?$-K>;!YBVDHF0-[$XXK#^(G_!W;IKV4D7A7X4ZA--(I5);Z\\G
MRSC@X"G->)ZQ_P &HOQVM;UUL?%W@6[A#85Y))(F(]2,''YUN^ /^#2[XJ:M
M>JOB3XB>%]'M\C<]G;/=/CO@$K5?5>&(OGYEZ7E^6X?6,YDN3EMYV1W/_!'/
M_@JI\9?V\O\ @I#]C\9>)KA?#=OH\\UOH]OB."-O-CP6V@;R <9(]:_;;4K%
M-3L)K:4!H[B-HW!'!!&#7P__ ,$R/^"$_@'_ ()N^,[KQ59Z]JWBGQ1>6WV5
MKJ[14BB0D$[%Y(R0.]?<^VOC\_Q6%K8KFP2M!)+:Q[^64:].C;$N\C^6C_@M
MS^PK-^PO^VMJME9V;0^$?%2#4])GCC*PC=D21D]-P8$XS_$*I_\ !,G_ (*^
M_$'_ ()M^*EALY+CQ'X#E9Y+CP\\VR,R,.9$;!VGO@8SS7]+G[4'[*/@K]KW
MX8:AX4\;:/:ZE8WT+1+*\2M-;$_Q1LP.UAP0?:OR'_:&_P"#2?5+?6+R[^%_
MQ(MGL9I-UOIVM6A#0@]C,K<_]\BOL,MXDP.*PJPF9;VM=ZI^=ULSY[&9/B:%
M=XC!?=V/0],_X.Y_AS)H8DO/ASXKBU';S#%M>/=Z!LC^5?GO_P %3O\ @M3X
MV_X*5QPZ$EK-X5\!V]QYZZ2D^\W; 85I#@'CD[3D9/M7L)_X-5?VAA?K'_PD
M'@'RCSYGVN7C\-E>R? C_@TAU&[U*&X^)7Q-BCM%YDLM%L\,Y]/-9NG_  &M
ML/+AW!3^L4I)RZ:N5O1$5/[7Q,?92C9=>A\ ?\$G/V!M:_;]_:ST71[&%1X=
M\-W$.I:Y/(C&'R%D&8LCC<PS@>QK^K?3-.CTO38+6%52&WC6-%48  &!7FG[
M)O[''@/]B_X:6_ACP+HMGI=K&B">>.%4FO748WR,H&YCZUZD%KXWB+/'F-=2
MBK0CLOU^9]#E.6K!TN5ZR>Y_/-_P=B#/_!0+P9_V*$/_ *47%>D?\&F!S\3?
M'O\ U[O_ .TJ^H/^"R7_  0R\5?\%+_VD]#\;Z)XTTOP[:Z3HB:6UO<VAF9V
M661]P(8<?./RKJO^",__  1R\2?\$S/%GB+4-<\6Z;XBCUJ)D1+:U,)CSLZY
M8_W:^@JYQA'D*PBG[]DK:]SR:>7XA9F\0X^[?<_0CK1117Y^?5!7\XG_  =#
MG=_P4;L?^Q:@_P#1LM?T=U^77_!6[_@@MXL_X**_M06_CW1_'&D^'[6'2H]/
M-M<69E8LKNV[(8?WJ^DX5QM'"X[VN(ERQL]3QL\PM3$8;V=)7=T<-_P:*?\
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g410427g06v12a.jpg
<TEXT>
begin 644 g410427g06v12a.jpg
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M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#_\
M$0@ *P#B P$1  (1 0,1 ?_$ .L   (" P$!              @*  D$!@<+
M!0$  00# 0$             !P %!@@" P0) 1    4"! (%!0@(#14!
M 0(#! 4&!P 1$@@3"2$4%187,2(8&0I!42,S)#0F-V&1,E(U-B<:\'&AP6)3
M5&0E5:9G.('10J)#8T5EM=569G:7:'BHV#FY2FH1  $" P4$! <("@\'!0$
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MD!P+*G1*G1JD:34VBS/@@921Y6!B"00=A!-IW)5.2J,D)^26')4@F(CLQ$#
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M0!S#W,6YT3+*E*:]-/\ 52M<;[H)2G$[A>3:JNHL[\ZS*M)*G2F  O)4M4
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MF(V!13+(@X]A-%Z7%6JDCIFFHX<KU&P$BYMEL")Z E";NF L=*Q4&*!17)R
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M^+&U4DY4CBH)!61DGB)UE/-33*J4$&R(#YB#<@F'0F3[9AZ1Z1Q/6)=+",B
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MG4..0F44.8YA$QA$>><G)JH32YV><6[-N*BI:C%2CO)-MTO+,2C"9:50EMA
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M8#/O3WB[?^*3_">GS>-[V71HRPQS>;O*_P!;,1ZS+GP':^UT6GM'R^SFOH;
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2/\U9H^*_JOT;^4[/_H?SEO_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image_0.jpg
<TEXT>
begin 644 image_0.jpg
M_]C_X  02D9)1@ ! @$!] 'T  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" #" _T# 2(  A$! Q$!_\0
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MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *",C%( <DDT8.[.>*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *,@]#2%0: H!S2]0%I&W?PTM5+[7-,TPXO[
MM(_0-26KL@+8 '0451TWQ%I.JRF*QODD(/1:O55FM&%[A1110 4444 %%%%
M!2'..*6B@!AZ9[]Z<SA$W,:BN;ZSLU\VXF"@=S7G/Q-^->F^&H)5M-10E<X
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !2$X&:6B@ )P,T Y&103@9-( 2<@\>E "T44@!'
M4U-P -DD8Z4,"#N!H8$]#45]>1V$'G2G@>M/XA,AU;5K?2[)[N>9$"#)+' K
MX<_;]_;VT_X1>(K;2[*^C?S9$3,9SU'M7=?MN_M?:+\-_#>HZ2ETL<VTA3OZ
M8K\//VNOVE=>^*OC,7BZR[K'>$CYNP)KZSA_)'BI\]1>Z>?CL4J,++<_:W_@
MGM^TS_PN;Q#)&UUNW/T)_P!FOLHL,9'-?BO_ ,$2/C<8/'#VU]>;B)@,%O\
M9%?LQX:U6/6M(CO8CP_2O.SW"?5<:XI:&V#JNK2NS1!R,T @\BD VCFCEN0:
M\3J=8M%(2 *;RQHW ?0#GFD4$#!IL\RP1F1NU)Z(!P=<9)Q65XB\3V.B6YEE
MNHQ@=V%<W\0?C%HWA&WD%R4SM.,M7S'\7/VA9_$$DMKI6H%<$C ;->!FO$&$
MRZ#5[R['+7Q,*2MU/1_C%^TU#912Z=;N,C/*"OESXH?&6\U4R7+7SCKP6K$\
M;>/;E%>XOKO?UR2:\>\8^,WU6<_9IL*2>,U^.<0\3XC$S?-+Y'SV-S!I6N/\
M9^.;C5YF_?,?F]:YO3;&?5M11%#-F5<X^M5W9W)#-DFO6/V5_AE<>.?$GE+$
M7V3CM]#7P=&E6S/&QI[N3/!2GB*RCO<^Q_V(?@TFBZ?9>(Y+89;')'IBOK5(
MT PJ@#T%<?\ !7PI:>&O UG9&WVN@]/85V0&3N'2OZER'+H9;EL*45;17/O\
M'06'H**$" =Z).V:=5>]N%MK&>Y<\1Q,W/L":]E;'4>0?ME_&JT^#7@$Z[)=
M(N(V/)]*_G2_:=_:^UN?]L*;Q5;:U/Y/S?*LAV_?S7Z2_P#!<7]L"ULOAC=^
M'=+U 1SPQ2J2K\U^$'C7Q-?>(]=;Q UP6D;/SDU^I\(94HX9U9KXM#X?B#'I
MUE3B]C^EK_@CM^TU;?$KX1)-=Z@K.T"8\Q^>WK7WC$WGQ+*&X901BOYTO^",
MW[6\G@6]TCP3>ZI@SE$VE\9Q7]"?@+Q#!X@\-:?>0L#YEG&Q(/JH-?(<2Y=+
M!X]M+1GOY-BUB,(K[HW%;=2TU.OX4ZOG>I[(4444 %%%% !1110 4444 %(3
M@@8HP=V<\4I.!DU-[[ %-,GH*0N3TXI5()QMJD&HX<C-%!.!DT Y&14W8"*=
MPS2TA8 XQ0W(R#BGJ*X!@3BEI.%&:-X]#1=C!FVT*V>#28WG(Z4I(3@"C9!N
M+13 Q%+NW<#K0 ZD9@M)N*C!ZT@!8]:%<!S-M[4H.1FC@\4@(S@4"Z"T444Q
MA1110 $X&32 Y&:'^Z:$Z?C2>P S!:"0!FD=23D4!P!@TP'#D9HI!DG(/%*3
M@9-3J 4@8$XH5MU*2!UJA7[AFBD)R=H/-*,@<FELQA1113 **** "BBB@ HH
MHH *#P,T4A8+UH 17R<&G4W ;[HQ3N@Y- M0HS32XQQ2+N)X- ]QQ.V@G S0
M"&HR"<4KH6HH.1D44ARISGCTIO+'(HUYACZ***8!1110 '@9I%;)QB@L!UI
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M[.N(&>#S2!6SDU^='QC_ ."N.E?#WQC)X?D\7"(KGY?.QWKEF_X+5:,%W?\
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M0#D4M>PGS,X6023/:W<,J$Y$JG(^M?L%_P $?/C;_:%[IGA>6\^YL^5F]?\
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MX[_M%>#OA#X5FUJ?Q%9K+'G]V\@SP/2OR2_;Z_X+>:AIVHW7AW0)!*DI91)
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M]*&7<<YK\V?^",Y)^$6BD_[/\A7Z3$'=G-?A>??\C&?JS]0RK_<XF/X^4_\
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MN ,YQ7)_L-F63XOAYW+.63+'ZFOUO*\CIY;E\I->\T?!XS,I8W%)?91_3O\
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M^/R<_9[W_OR?\*%BL(_M(/88CL>/?;]8)YUZZ_\  I_\:7[?K 4_\3V[Z?\
M/T_^->Q+^Q!\0",_9[W_ +\?_6H;]B/Q^XP+>]Z?\\/_ *U'UK"_S(?L,1V,
MO]CF_P!7D^)VU]:NF&].#<MZ_6OZ?_\ @F&9&_9SM3)*SG]WRS9_A-?SM?LH
M?L;>.-&^(OVB>"\ W+RT/_UJ_HS_ ."='AJ[\*_ 6VTV\#!QY>=XQ_":_/\
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MO*O(E.QO- Q@&OYX_P#@H3^WEXO^//BN4:3XB\R!;EE9=Q/ R/6NS_X*:?\
M!1'Q=\7?'UQIVC:IY]E.S[F\X^OI7PT=\\[W$G5W+'ZDYK]=X<X?IX"BJM5>
M\S\_SG-IXJIR0?NH=*TMQ,]Y,?WDARQ]37KG[#&/^%O G^\G\S7DK*0I.*];
M_8;'_%W %_O)_,U]+BG_ +-/T/&PUG6BS^GG_@FWC_A0,'_;/_T$U]" @CBO
MGC_@FX2/@' I/_//_P!!-?0X ' K\#Q[_P!MGZGZKA?]VCZ''_&$G_A"=5Y_
MYALW_H!K^8+_ (*@%F^,/B$?]-V_K7]/OQD^7P3JO_8-F_\ 0#7\P/\ P4^(
M_P"%P^(1_P!/#?UK[/@C_>9_(^;XF_A1/DV'*V_%>O\ [&F@V'B+XUZ'IVIP
M^9#+/AU]:\@B_P"/?\:]M_86)_X7WX?4?\_%?I.*;6&F_)GQF'2=>-^Y_1C^
MRA^Q1^S]K/@VQGU'P?O9]/C9CN7J4'^S7K4G[!'[-AZ>"?\ QY?_ (FC]D L
M/ ^G8'_,-B_] %>T5^$XK&8F.(:4W]Y^J4*%!TE[J/%5_8(_9JSD^"1_WTO_
M ,31_P ,%?LU%L?\(3_X\O\ \37LY!))Q1M&W.:Y_KF*O\;^\U^KT/Y4>-?\
M,#_LV?\ 0D#_ +Z7_P")H;]@G]FH#CP2/^^E_P#B:]G7)'-#$8YYH^N8I?;?
MWB^K4/Y4>0Z+^P_^SSH=U]LT[P:$D]=R_P#Q->E^&_"VC^$]/&E:':^5$O1<
MUJ=N/3BD&!R>N*RJ5JM;2<FS2-.G#X581?EZ]Z\W_:2./ >K<?\ ,-E_] ->
ME8!YKS/]I/\ Y$35?^P;+_Z :O"I*O$FKK!H_EX_X*'D)\:_$3$?\O1KYTCB
M66'=BOHK_@HD=WQK\1 _\_1KYXMB1 ,5^_8'_=(>B/R?$I?6)/S/1/V??C]X
MU^#_ (UL+_2]7\BV@?+#G_&OW:_X)6?\%1/"_P 0=%ATGQ;K7VB<Q")/WXZC
MCOFOYXFC5UYZ^E>B_L[_ +1'C'X'^*K&3P]+LB6Z#2'S",#->;G634,TH-->
M\CLRW,JN"JIIZ']@_A[7+3Q%I%OJ]D<QSIN3GM5U^E?FS_P2[_X*:Z!\4-/L
M/#7C'Q,=T,8C*^9NP<9[GWK]&M!UW3?$FF)JVES>9!)]UO6OQK'X"O@*[A41
M^CX7%4\524X,MH#G(IU,+8/RTY<D<UPM.QU"UX/^WL<?"XD_\\WKWBO!_P!O
MC_DEI_ZYO75E_P#O4/4PQ/\  D?S"_\ !0D@_M#71'H__H5>*R$B!OI7M/\
MP4'_ .3A;GZ/_P"A5XM)S PK]]P?^Z0]$?E.)_WB7J?9_P#P2#_Y'"'_ *_3
M_P"A5_2[\!/^22Z+_P!>H_G7\TG_  2!7/B^'/\ S^_^S5_2W\!?^23:-_UZ
MC^=?FG&_^]H^VX;_ (+.PHHHKX0^G"BBB@!"H;K0K9.WTI:;D*Q(H%K<7 )S
M0S;3@T!P3BJ'B+5X-'TV6^DE4>6N<%J(0<I6$Y1C%MF?XV\6V7AZPEDFNE1A
M&2 ?I7QY\?OC)=>)KB;38Y&*HVT$&NG_ &D/CDVI3M:V5P5YV'9[<5\_W,TU
M[>274TI;>V?F-?H?#V3*C#VU1:GY=Q1GSQ$WAZ3T1#<3.5^TN3D^M> ?'/4V
M?7'A['->]:S<"WL]V.F:^<?C)=BX\0$_[U?I&2PYL1<_.,?+DI;G)>&M3GT7
MQ#:W\+']W,&^4XK]"OV.?VM((-,^Q:KJ:Q>3 P7S&ZX4U^=L:@?,.M:N@^+]
M8T%S]DU&:/=Q\K5Z'$.34LXP;@]UL7PUG%3*,?&5_=>Y]B?M:?M8ZAXKBN=%
MLYV:,;@K(W7-?+%U?27\W]H7<A]RQID>K7FL#?<W3.6Z[CFN?^(OBJW\.Z!+
M(9%!7WK\QIX'ZE+V,4?OE/%T\3056+W1P_Q[^)T>BPS:=;W .\$<5\K:QJLV
MKWTLDI.#(3R?>NE^+7C:?Q3J_G1SMC>>,UQ\8&2>^<U]%A:*I07<\NO4E4F+
MC:,BE^\.12TTK@[LUT63,+W' X&!2;AG YI=V4P*;&I.33LV5I87((X-1W2E
MH\"G[,'(-,N)8[9/,=Q^)H4K2U(;LFV?2?[&/Q"CT?6[+2IKK8#C.3]*^\M?
M\?VJ:8!:W2OF$?=^E?C_ /#3XN'P]\0K6&.8@#/W?J*^]/A9\0I_&FC"<7+-
MMA'4_2OY8\=,#/+<5#&05N9?FSE>8)IPBSL_$GB6?6)W5B<;O6L@DGJ:#G>2
M3GF@'!SBOYCG4E.7,]6<4KN5V+QCKS0K'&#3=N6SFE)V@@BHMJ2]Q2 #P:CF
MW$ *.IIRM@$GFM3P;X>F\3ZD+2%6)$@!P*:@ZDE%;L:BV['T/^Q!\''U/QG:
MZM/:_*VWYB..M?I1X<\/P:#9_9(  ./NBO!_V.?A%#H7@JRU1[=0_')'/05]
M%5_3/!>41RO*8W6LM3[O*\,J&'6FK   8%%-V>]*[!$+GL,U]F>H<]\2/&UI
MX&T,ZM>7*Q*,_,QK^>O_ (+0?M:W7B/XOWWAJPOFDAE\WE'XZBOUG_X*S_M(
MVGPR^!D]Q;7R)(@E^X_/05_-A^TW\4;KXK?$A_$4MR[AM_WCZD5^A<&98YR^
ML21\AQ)CN5*C%G 0;C([MGYF)Y^M+)N>ZAMT&3)*JX'N0*>?D3([5O\ PL\&
M77C;Q9I]K;PNX.H1 [5S_&*_3)2Y=7T/BTG*5EK<_2K_ ((8_LL-K/Q;M=:U
M+3ML<LT1#NO%?O=X.\%6?AWPXNAPJNQ>P'%?&G_!*/\ 9CA^'WP\T+Q6;%4=
MXU8M@9XQ7W8 $7 K\4XDQ[QF/;6RT/TS)\(L-A$NK/R%_P""X/[+@\4ZMJ?B
M^WT_>(2[;E7ZU^$VK:?/I&O7MI+&5\NZD7GV8BOZU/VZ_@I:?$/X-Z]<M9H\
MC6YP2.:_F+_;2^#%W\)O'%^);=T$FHR$97L7-?;<'9BJV&=&3U1\SQ%A)4ZR
MG%;GC,T*R(&S7TU_P3,_:"O?A=\=K:YDN7CCC\O!+<?>-?,L9)0$^E7O"/B&
MY\':V-9MYF1ACYE-?7XFE'$4)4WK?0^=H594:BDNA_7-^QM\9+7XO?#E=>%Z
MLA*H00?45[)&.]?D[_P1&_:_@U'X767AF^O@TLRQ >8W/2OU>L;A;FSBN%(.
M^-6X/J,U^%YM@Y8+&S@UI?0_4,NQ"Q&&C*Y*% [4A.YMM*K9.,4A&T[J\O?0
M[P!*G::X3]HOQ9!X7^$^MW[3A&BLRPYYZBNZSELU\K?\%'_B,?#/PI\062S[
M2UF1C/TKJP='VV)C'S1SXJI[*BY'X'?\%4_CQ=_%'Q?>:>UTS""^VCY_1J^0
M(L&,;N_<UVGQ^\43^)/B/K)EF9Q_:4AY/^U7$W1,4 .>:_>\%0C0PT81V1^4
MXFK*M6<F=E\"?AQ=_$[Q_#X9BM6D$F. /4U_0C_P1[_85T7P)\+X-1U.RBCG
MABC(62/G^5?E+_P2 _9_/C#X[Z9J5S:^9&^S.\<?>K^DKX5_#^S^'^C?V;:6
MZ1*% VQCTKX7C+-9QMAX,^JX<P,7>M);'2V=G#96T=O$B@1H%&T8Z"GA<G!I
MP.ZAAN&*_-&S[->0UB?N^E.3I05!&* ,#%*W8?0  !BD\OWIU%/H&H@4#I2.
MHZYIU(R9.<T6%U&J<''K3F.T<"D"8.<TZDKC&<[6/L:_-#_@M0!_PI?5#_UT
M_E7Z8O\ </TK\SO^"U )^#&J#_KI_*O;R%M9C!>:/.S6RP<O0_G>UW_C^'^\
M:BT[_D.VG_75:EUS/VT9]:BT_C7;3G_EJM?NJV/RV_O'[9_\&]HSXQ/_ %T_
M]D%?M#:@"$8K\7O^#>S_ )'(_P"__P"R"OVAM?\ 4BOQ7BK_ )&LC])R'_<$
M24445\V>T%%%% $-_P#\>Y^E?B#_ ,' #8^(]P/^FK_R-?M[J!Q;DFOQ!_X.
M "#\2)\?\]9/Y&OIN%/^1JO1GAY__N+]3\:)_P#D*77_ %V;^9JSH7_'_'_U
MT7^8JM/_ ,A2Z_Z[-_,U8T(_\3",?]-%_G7[0_A/S=_$?T8?\$:1_P 6>T4_
M[O\ (5^D9/.".M?FY_P1I/\ Q9[11_N_R%?I(1GO7X1GM_[0GZL_4LJ_W.)C
M^/0!X+U+'_/JU?SV?\%REW/<_P#77_V>OZ$_'HV^"]2[_P"BM7\]W_!<IAFY
M_P"NO_LU>QP:FL>C@XB;6$/S,M1\@4G\:]-_8V3_ (R(TH#T/_H2UYC;M\@P
M.M>G?L99_P"&B-)_'_T):_6<3?ZO._9GP.'_ (T?4_H;^%%O_P 8B^)R&P?[
M!'/_  )*_#_7OVEO$?P ^/6IW6ERSE7\09;9)T!D&>IK]P_A9E?V1?$W_8!'
M_H25_//^U\Q/Q5UQT."NJN01_O5\1PS2C6Q%>,M5='TN=3E3A1<3^A3_ ()D
M?\%#](^,?A72/"FM:_$D@5599&Y&<>E?=]CJ%EJ4 N;&X66,]&7I7\E'[$7[
M8NO_ +/'C1-;N-8N6B1U(CW$@8^E?T.?\$\OVYM"^-?PZLA-J,'G3;>'D ;D
M>AKY[B7()X*LZM->ZSV,ES:.+I\DW[R/L!B<[?6D.R-2S' [DTT30R 21RJP
M_P!DYKBOC+\7='^&WAN]O[Z_MXS%:LX$DH!Z>]?(0A*<N5;GT$I1A&[V,3]H
MO]H+PU\&O#KZG>:]!"?)8_.?K7X%?\%1/^"E7B+XE^*-3\"Z==RR6IW;9(Y!
M@YR/6NV_X*R?\%/[CXBR7_@CP]J4L36K-%N@R,\^M?F#KVN:CXDU5]9U"\>5
MI.ID;)K]4X9X>CA8JO66O0^&SS-W6?LZ;T*\]Q/JDHN[N5BWJ[9IW'53TK0\
M.^%]2\37R6-C8S.).ACC)'Z5K>./AGJ?@%DCU&"5-X!'FH1U&>]?;N<>91N?
M+\LFKHYEVRO3M7K7["^?^%OCC^)/YFO)20N>,UZY^PN<?%\'_:3^9K+&*V&E
M;L;8:/[]'].__!-Y!_PH2#_MG_Z":^A*^?/^"<#9^ 4&/^F?_H)KZ"3I7X'C
MU_ML_4_5<+_N\?0Y#XR_\B3JO_8-F_\ 0#7\O_\ P5  'QA\0@?\_#?UK^H#
MXR\^"=5'_4-F_P#0#7\OW_!3_P#Y+#XAY_Y>&_K7V7 _^]3/G.)U^ZB?*$'_
M ![#\*]L_87R/CYX>('_ "\"O$X?^/7CVKV[]A,9^/7A\?\ 3P/Z5^DXO_=9
M^C/C,/\ QX^I_41^Q^Y_X0C3N/\ F&Q?^@"O:B 1@UX3^ROKFGZ+X'T]KR\A
MB_XEL7^MD"_P#UKTH_%GP?'*8V\2Z>".H-XG^-?@>*A*5>3L?JU&48T4=6W"
M\4BJ" :Y8_%OP<1C_A)=._\  Q/\:<GQ8\($<>)-._\  Q/\:P]E4O>QJJD&
M]SJ&8CH*97,O\6?" Z>)=._\#4_QJ6T^)WA:[8)!X@L').,+=H?ZT.E.VP>T
MC<Z0G:.!32=S?6F6]U%=VZSP2*RMT93D&GKU%9Z%(>  ,"O,_P!I5RO@/50!
M_P PV7_T UZ97F7[2C ^ M5R/^8;+_Z :WPW\9&=9VIMG\N__!0[#?&OQ%D_
M\O;5\\V_$0 KZ$_X*'?\EL\1?]?;5\\P2;+<$BOW_ K_ &2'HOR/R;%:8B7J
M2TA0/R#@CH:ZSX=_#>Z\>W45G:!BTI& O6MCXS_L^>)/A$83=:==E955LM"Q
MZC/I6GM:<9\E]3)PGR\UM"Q^S/\ M)>)/@!XH35=+GG;=<*Q"R=.@[FOWW_X
M)D_\%,M,^*GAK3/!_B'7HHF^7<LK#(R .WTK^;EU<OMP593T(P:]8_9=_:?\
M3_ ?QM'KXUJZ\F/9B-6) P3V%>-GF24,THWVD>GEF95,#56ONG]?.EZMI>LV
M_P!LTF]2>/\ OH>*M*<C-?GG_P $Q/\ @I9H?Q9\#6FCZE?P^?.(^9FPW3W^
MM?H+IU_:ZA;)/:W,<@90V8W!ZCVK\;QN"KX&NZ=16L?H^&Q-/%4E.++%>"_M
M]DCX6G_KF]>]5X)^WZ<?"T_]<WJ,O_WN'J5B?X$C^8?_ (*#'/[0ER?9_P#T
M*O%F_P!2WTKVC_@H*<_M!W/_  /_ -"KQB7Y83]*_?L&O]E@O(_*<3_O$O4^
MTO\ @D#_ ,C=!_U^_P#LU?TM? 7_ ))-HW_7J/YU_-/_ ,$?P#XM@_Z_3_Z%
M7]+'P&X^$^C?]>W]:_,^-_\ >T?;<-_P6=?1117PA].%%%% !32A))S3JCEF
M$()?@>M+?0"+4;Z+2[<W,QX%?._[1OQSMK-Y])M+H(7R  U=-\>OC)9:-I<U
MC;7>)5SQNKY \:>++[Q1J'VJXEW').<U]GP[DSJ/VU5:'P?%&?*C#ZO2>K*.
MJ:K?:M=R37<V\&0D9^M5L-C - !4<FE'7BOT"*M'1'Y@^9[]2AXME$.CEB<'
MGFOFCXHSF77R<]S7T5\2+H6OAXR%L=>?PKYE\:W1N]7,@.>M?19%!J\CRLR:
MLD97(H++D&DZGDTXHI&1Z9KZ;1;GD.[::-&UUN+2XQ/.WRCL37@7Q^^*INKR
M;3;:YP&SQFO1?'6OF*Q,%O)\P!XS7SC\0XKNZUEKF8<<YKX;-*%!8YRB?L7"
MU?%/*^6KM<Y<22SL7E?//6G+CMBD8A3A*&^7[M<RMN?0-::BE=U*02-HZTF<
M_=-*#COS1HQ6?03.SY6ZT@RQ^7-.V^8<_K39YX;2-FD.,"BXF[*[":=;5"\G
MUKA_&'C*-M]K;R88>]/\8^+CM,5K+R..37#7EP]S,TKGD^M=&'H\SO(\?&8S
MF?+$M^']6N+;Q+%?R2GY<\_E7WW^Q?XWCU?PXRF3)\L#K[BOSU0F(^=Z5]2?
ML2>.S86Z6;38WG&,^]?E7C5D,<VX4G4BKRC8X*,O?/N(@&,2>HXIHX.2:;8S
MK<Z7!*ISNC!IW6OX'M*+<7T.X"<G(I=A(I ,<"@L5'4T(+6&[0KA#U)P*^A/
MV(OA++XJ\89G@WJ91C*^U>#Z!I5SJ^LVL$2Y#3J#^=?I'^Q+\'XO#5I::S+;
M;3(H8G;7U_!F4/-,WBVO=B]3TLKPSKXE=D?0WPV\/1^'/#<6G+%MV=JWV)#
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M21^73UF?M#_P1%^'UB+G2-<-F-_R?-CZ5^WI&P_+7XX_\$1KFS_L#2(\_/\
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M_A_QIP_X*G?&''_)09?^^S_C7Q_]CC(QBD^R(!TKZ/\ LS!6^!?<>)]>Q/\
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MU'$X6<)H_D]_:J_9A\5? ?QEJ9UF-EA2Y(12F,"O(D994!CZU_2%_P %0?\
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M!7KO[7WP]N/ WQ$U=Y;=D#ZD^"PQU:O)VC\V 5^]4)J=&,D?E,X\E1GZW_\
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M9E./EY_ 5^CM?A6>O_A1GZL_4LJ_W./H8_Q!X\%:G_UZM7\]'_!<ACYET/\
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M6O,K0GRP*]-_8U!_X:'TG\?_ $):_5\1K0GZ,^ H?[Q'U/Z>O^"< Q\.P/\
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MO17%K=JSJ#E5/-?&X3"U<775."/:QN,I8.@ZDWL<[^T)\;H=.MKC2+.^R3G
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MN,5\4_M'_P#!9;XZ>.()["._:2*3/_+T?\*^$9Y;^;YIM3G.?[TS?XU#<!C
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MP. Q.>U>Q_L%D'XR#!_BC_F:_5L;_NL_0^&PW\6)_3S_ ,$YO^2#0?\ ;/\
M]!->_P!> ?\ !.;_ )(-!_VS_P#037O]?@6-_P![GZGZMA/]VAZ'%_&W_D2-
M5_[!LW_H!K^7O_@IL,?&3Q$/^GAOZU_4)\;?^1(U7_L&S?\ H!K^7K_@IL__
M !>;Q"/^GAJ^UX(_WB7R/G.)OX43Y:@53;8KUS]COQ1I_A'XR:)J^HW/EQ0S
M@LWI7D=G@P@$U<LM0DTR87$+D,IR-IP:_3*L/:TI0?70^(IS<)J78_IE_9J_
MX*'? ;1?"-C:ZEXY1'CL(U(XX(0#UKTQO^"E_P"SJ#@?$!#^7^-?RXV?QO\
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M.-2'# \?X5Z[XYI-.T&>?'AFHI:R/ O^"37[(B_#CP%HWBBZTX)*0I+.N#P
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MN?#G_@EY\,/!6N?VM8^"%B?(^;8/\*^UK\8X.K1E#EW/FZ/#N)IU$[Z'KO\
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M_@,_^%?TV?%3_@EGX$\=^([O6;OP:LC7#[BQCZ_I7)M_P1W^'6S;_P ((O\
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MJEF)5G3# ]Z]++<QK9?B%.#./&82GBJ7+)'\YO\ P36^$FN_"?XFRV&H65P
MFK.@,D1'\9'I7]$GP();X4:.Q&,VW]:^<K_]@#PWI/B9-8\,>&Q"3=B5V"=>
M<FOJ;P-HK>'O"MGH[+@P1[2*]+/LRIYDXSCN<F5X.IA+QD:U%%%?-O8]@:?O
M_C3J**%L 4444P"BBB@ HHHH *:?O_C114QV =38^]%%+N ZBBBG'8 ILG:B
MBJ$MQR]!]****!A1110 4445,=@"BBBJ ****"7N@HHHJ9;%!2/T_&BBFMA+
M<$^Z*6BBA[#"BBBE'8!'^Z::O4?6BBJ ?1110);A1110,**** "BBBI>Z *;
M)VHHHAN3+8=1111]H:V"BBBC[0PIC=3]:**'NB5L+_RSI4Z?C115%"TU.OX4
M45,@%?[IH'W/PHHH?P@"=/QI:**4=Q/8****L2W"BBB@H****3V ****%L)C
M4Z_A2O\ =-%%*.Q,=P3[HI:**/M%A2#[Y^E%%43(6BBBI^T-;!34Z_A115#'
M4-T/THHH ;'WIU%%-[D+81_NF@?<_"BBHCL4]A$IU%%#^(%L(_3\:$^Z***H
M&+1110,**** "BBBI>X"/T_&@_<_"BBD_B $^Z*1^OX4458"-_4T]>@^E%%)
M[$]AO_+2G444HE!1115 %%%% !2/]TT45'5@*O0?2ANA^E%%..PNHB=/QI:*
M*H'N%(_3\:**G[12W$C[TZBBJ![A1110(**** "BBB@!'^Z::O4?6BBICL L
(G:G4450'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139828568944800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Nov. 13, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov. 13,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Acumen Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40551<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">36-4108129<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">427 Park St.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Charlottesville<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">VA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">22902<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">297-1000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ABOS<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001576885<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>abos-20231113_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="abos-20231113.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001576885</identifier>
        </entity>
        <period>
            <startDate>2023-11-13</startDate>
            <endDate>2023-11-13</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-22">0001576885</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-23">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2023-11-13</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">Acumen Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-40551</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">36-4108129</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">427 Park St.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Charlottesville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">VA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">22902</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">434</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">297-1000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">ABOS</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="c-1" id="f-21">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0
M   ( 'TZ;5=508'K[@   "L"   1              "  :\   !D;V-0<F]P
M<R]C;W)E+GAM;%!+ 0(4 Q0    ( 'TZ;5>97)PC$ 8  )PG   3
M      "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ ?3IM
M5P[\IJ5:!   $A$  !@              ("!#0@  'AL+W=O<FMS:&5E=',O
M<VAE970Q+GAM;%!+ 0(4 Q0    ( 'TZ;5>?H!OPL0(  .(,   -
M      "  9T,  !X;"]S='EL97,N>&UL4$L! A0#%     @ ?3IM5Y>*NQS
M    $P(   L              ( !>0\  %]R96QS+RYR96QS4$L! A0#%
M  @ ?3IM5ZK$(A8S 0  (@(   \              ( !8A   'AL+W=O<FMB
M;V]K+GAM;%!+ 0(4 Q0    ( 'TZ;5<D'INBK0   /@!   :
M  "  <(1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (
M 'TZ;5=ED'F2&0$  ,\#   3              "  :<2  !;0V]N=&5N=%]4
?>7!E<UTN>&UL4$L%!@     )  D /@(  /$3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="abos-20231113.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://acumenpharm.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="abos-20231113.htm">abos-20231113.htm</File>
    <File>abos-20231113.xsd</File>
    <File>abos-20231113_lab.xml</File>
    <File>abos-20231113_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "abos-20231113.htm": {
   "nsprefix": "abos",
   "nsuri": "http://acumenpharm.com/20231113",
   "dts": {
    "inline": {
     "local": [
      "abos-20231113.htm"
     ]
    },
    "schema": {
     "local": [
      "abos-20231113.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "abos-20231113_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "abos-20231113_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 23
   },
   "report": {
    "R1": {
     "role": "http://acumenpharm.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abos-20231113.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abos-20231113.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://acumenpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://acumenpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://acumenpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://acumenpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://acumenpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://acumenpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://acumenpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://acumenpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://acumenpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://acumenpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://acumenpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://acumenpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://acumenpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://acumenpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://acumenpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://acumenpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://acumenpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://acumenpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://acumenpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://acumenpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Ex Transition Period",
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://acumenpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://acumenpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://acumenpharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001576885-23-000058-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001576885-23-000058-xbrl.zip
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M$1F)<*K&F)..\/"(2N*Q(2RA;\HDZ6BK2F[?P%M>O"N3 XQ?ZH<Z)9UUAF6
M4A'>L<%CRY48T!F8:1IPNWM]2=]L#8P';\RPLE0QYX>&9YO1GFPFK4-(=_!B
M"9)'W2G+-O))[Z.3;&-3;D2)>/F<B&6T9UM71N2#8MWA/>)2 "'9*'O\UOGL
M&"1+:QV0K"#4P7\LF>X%B$Y/@?$U':X/>),G/1"?>BU_CHOK-Y=02@/8&[0(
M=LTEC -YI8&+J7?JNGBQ!COCNSH>%9Y,SG^]>S,/Y0.ZR#RLRF#Q%7+F[&J!
MQN3BZ\//W-CWI>S>3O+E=;U@LOJR3!0F!&T)YE,LUKOUULP2#+V^M1Q"!^ <
MQ>KVD(>>I]GUC9RZD8T9BZ5'-V+F0##ZS:1#L% MZD_I7!JEIWY(9Y/6;+R
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MR#WV<4U2N;BRU!13((2"IX8<()7A/ZE8 )>%"UDRUVAC'.ZE]XBY9V1<-N;
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MEFDYP:,MTQ?C#^*[B!PO)OY C(&%8ZR+/Q=7=<T^8+<%;:-N9-(=[:-^%@;
M)[*%8C^,F"OZ(HK 0@W[\ =4&<])#SBXH-%ZP"-]5 ]3I'[*\O\1+U4AVW$+
M@7,2;@VT%YJ[RJ-R>*KVJ$.<!$@O[%;QP$3)7%1'I'00UZ&..YB@3?P'@V'T
M!XR(W7.?=!+\,!)Q$GE.(N3WVD=>JQN=3D.[R$\"FK6&46OMV..E9/SGB+2>
MJR(<A_&$)4/!>F+@!0'J0F&?/AC#R\/U0VQ/S/ZNF89E%NTVK-TC+ZB36LT#
M=H0_975E)W8AL/)T$Z/8DKVKN8$;)M46E7ZEN=?MI[WL\TK*2<"=!K#7'=O"
M[.-:#JSX:6+0Q)"39HV6T:COV//VD-2@!VW/S=IMKQ^T_5,O="?PGV$R\M_]
M?U!+ P04    " !].FU74U#1B-T+  ")+0  &    &%B;W,M,C R,S$Q,3-X
M97AX.3DR+FAT;>5::W/;-A;]OK\"FW33=D92)+]?S8QJN[.9-DX:>YN/'8@$
M):Q!@@5 R>JOWW,O2(F29<?>V=II-Q\<B22 ^SSWW$N=3$)NWIQ,E$S?_.WD
M[]VN.+-)E:LBB,0I&50J*J^+L?B4*G\MNMWZJ5-;SIT>3X+8ZF]MBT_67>NI
MC/>##D:]:?8Y>1V_G[SF0TY&-IV_.4GU5.CTNQ=:'6RE6XG<V>_O[NZHP9X<
M[*<[V<%NFO5E<CC*?AV\P%(\'M?X,#?JNQ>Y+KH31><?[6V7X7BFTS Y&O3[
M_WBQ^IQT8SP:;'DTV,)S0=V$KC1Z7!RQ]'@ZLT6 5 ZGQ(^W#FLM2J"0<O_K
M5?>M;8O9W$ZLL>[H99__'=.=;B9S;>9'7Y]BU<CIKSM>%K[KE=-9?,#KW]71
M8  ;\-=9--X^UAM=J,:8T8+G-Q,]TD$<'O:V'J6?SL="F@"WYG*L?NWW_EV.
M7PCODO4K<8OZT.V#\N:X]M3(AF#SHUW(.54NZ$2:^A ^+]YNW'VX5]YLC(Z5
MO0Y6_?X(%Z[NT^_U[]OJ"9RSM0OG##FMQ(>)=+E,5,4V\N)2)9537GRU"SG%
M.VV,MH4X=2J%(W^0B38ZS,5,AXGX<4O\4\%-DU\@/RUZH &@_6/,1DFW!Y5*
MF:9 D*Y1&70X:%UQ4:V-5HU7=)'BVU%WL#S[ 7:^TCDL<:%FXJ/-9?%0>^]L
M3(97+P^VMO:.&VW_&%=O.GK-<#N]P2X9X8.S4PTP%G0WP,G2B$26.N#_8(6O
MRM*Z(%(U5<:6C.0V$Q(W1DD59*%LY45F75X92<OI[O#T7X/#;2&+5(Q5H1QM
M:1WV00$0985/_IXH69%S>^]Q45+'UI\[4/9WGBU0</0=@?+5=E_D-0ZD3L[P
MU^*/#,)868C$6"KL#\EB*IU/B'*4=:> -X/04'X*%51'_#+L=<2%G?;$8+O#
MI..)#<UB"7+R8' LGO[P&.>I2B@KX=.C"B'OZ*F[:D)'O"V2WK.8Z9N+X>79
M\.=7+W</CL7P^_>7WXIO.#_ZQU%6_@([6B?"1(GZWJG-2UG,ZYO?=@!;"79G
M%N #"(08:5NN: F@XC4-X!%7E:*P^$([.UGR@_B,P ^(:14\</(&E[PUU<@H
M(?.YL3H5(Q6DL( 6FROGEP*_>GFXLW?\WC=B$7JRU($8<H.P0_,[;("5'"+[
MQUZDVBOIU7*CLZ5BP:9R#L M;%4D(-DL'BKU1'K!L(9KN@"> [A5H7&@YP*?
MQN0EI.8+5-3EV"G%8GS3LN5/]-RPN;60?3,#($M/^$HBG>IFX.X>9_E2)1I7
MYR+3A82@C;5[XH&X3D3N?B09R>1Z[&"&M%N'9<;_CO_H(*WM] D!X%#E#/DJ
MI1+:> 5.T;YEW;M-9W2FA$^TPBH/OTV5CW&1:9>+ZX)PEX+&!ZJH8\3>\AEZ
M7I3.YIK[K*47:EMK'-%DBY<(TS.Z9L3[.LY.;5$H8SKB X315 4Y.DXG6F7B
M_ 9!$O14B?=9IA/E.%(Y WNO7@[V^L=-N%R1KM'+)$;9L R0!=:[Q39LJ2($
MX7-FU UZ!2:7*<*1LP_WM4W%; ),FD7S&AC7+>(*%4E%R6S1 TJ)4A+7!R-Q
M'<ZL#.% >\T _@M*8RLGG**J;]JITV8Z$'OL9,[&WD!YEERG ZLGIDJCP !.
MY.D _JE2D.2)3B8DN+I!_ <*"6!0T$2&X*M<IUW4GYU>[96_6B:HFT2'F GD
M%M#!& %UD8'OPFJLM%@G2!10N@$<1L$IXCJRS!6$+FW 4P 7P*XG_M9-$".^
MA:GD0P46,-\ K6<16E<3XX+8W$1<3N2D(]Z1)'34F4;,!(J'<#MY>W>$?V:-
ML3//(5<G[9Q4J T20Q,V*:&:BM_;&+!,W;;2"]5\A/N)G"J.]J4M8$J<5G@.
M5H.\]7^=*+N"IJM%J84R):D>>]>&LY8P:Z)+6 5)AXJ8<^GS*T7NBB[3IHOZ
MEMC":Q_(WMSV (%]8*,F6(9+H,7+0SI-LJ/L$N8@[.&8FAIW&$BI &/3M+U'
M+>Y66]RX48ZJ/E+-7A!<%R NQD2W5R5GCQ(MHL/Q[-1O%=*@0Y#U[QISG)IJ
M=":C.:\PBNB>I],!XT'RUA0FL8G+4$#:.[/H("")4XS4#E=*,C=A=O-LO6=/
MD&L6IH0.G!N4Z2#<*A\! 0;,N?=YVUI'T%'%6D+6M><.A,Y6I4E0CA#-"]F7
MJ0;[07.D$>08+HM,"C*F#5EF+!W#=+@=/UP>1JK&\FCP3>;]N4+>*H*2CRJ6
MDD+\0"DVZ'=_7M"YW^)3(FIUJ<H0==KNQX:C]\ <'.Q\-@G_Z/9I.+)5$ ]I
M"QX\\WFJWB$*W2$BE-8>B8[=T!)V(@IO:G&>#>;:1(DY%Q.\M^ SJ$@EV@MR
MP 4GTH6:!<*@=\/G:-) @?SS-EB+SNKQ+=7P[-N>6+:2?).+;]"P.;:K(ES6
M!1H1!$0#FP!$(_<7!S?X+P5B94:JT>L).EM18:)2KN&Y! 3 1W+$A(2<!Y)+
MA89$#4Z/QS4XWRUS*<,$+AW/&\')_FCA7"2T+6XLTVD-CCHT[80>-Y0;*)Y6
M*!$)I- I).LL."V:N H4#$$ E+:%12&C%1)68;W81UX95!AP"QRZV5\M\T0B
MQ!T!:B)W$H T"B8R:&5B^_+VXNK\X^GYAZON\*S3XM--;)&%N(Y/K9G29G?Q
MNI:MR)<H"8!IJ.)4N]IUF%2&+VP(,YO->I(=RPG40]Y\%F77RL/]$]-:CGUZ
MD16] 0&<HC'N5-WY"JQY>[%<(D?DZ'![R6=>4,6_$[><^XY5=X2$O>[*##!]
M),U,SOV+_Z<W=9M>$?W7AWZ1K\\>H=,]"Y_X[1A08P;:V/W)VFO"F\L G(QO
MHS^?D$_/>;C[+ &HQ'=Y$$5]#!%EGENP*J96Q3>JQ,%,S7AS!=B//0^1^0].
M3VE<<1EGA-2(_J2;&@(2S/WE,.$J.S@\W&V&04/4^<4!J/CH'_2(]ETKM6/+
M1#(.2'A3JA61TQ/Q<<(2-Z!:1>U,O*\+;G/QF1X8*:-5YB,)N5/)..F<V,H0
M?8C=7<KUG*:@H>NTOUX^7:OQR;H4=*"BPNZ;5A%=RV)<4%^*XOOURW57FC:7
M600-=TM'&I.;6 G)56G9!/'P36?S>US6H?R&-N,)&!240_MRCW_K&" '(R*:
M[7GX0!KV%F&^86W=$JUMA_:KV.#.TE!CW9YSK<_$B)\1&5D9J=TU>:M?)[9F
M99WU$V4],^0^-U'$*Q[::'/)W=0-DI]6QRD-J^2.ED>4I)O--JW&.:VFEGMB
MOV(^<O>(9\2+-KYF;XM8)@G:.;&<MK8F8_58 ;NUFOU%7RQI5H4XH<".&]*4
MDV]2&G=:HU+B;Q-+D5$@UTB.&@S@BX2PA&9NVB>@ZH['&6T&CXU!4,"]*&'U
M[QP],E-1A2R+##'2R3;-1]!=4EY%\>I)@,S!"#,-R]3#"HV. 8E% HR5I:8G
MMA(XGRW)0X3$6?*WS<$\R>^ZAHDF;UT<B(/WU2^J:9GF=R,^")K)\<-E"3M
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M,RYH=&U02P$"% ,4    " !].FU780%7SFL"  !M!P  $0
M@ &8$   86)O<RTR,#(S,3$Q,RYX<V102P$"% ,4    " !].FU7__UE:*$*
M   !80  %0              @ $R$P  86)O<RTR,#(S,3$Q,U]L86(N>&UL
M4$L! A0#%     @ ?3IM5X8XW1O>!@  \S(  !4              ( !!AX
M &%B;W,M,C R,S$Q,3-?<')E+GAM;%!+ 0(4 Q0    ( 'TZ;5<.%N$':24
M -+R 0 8              "  1<E  !A8F]S+3(P,C,Q,3$S>&5X>#DY,2YH
M=&U02P$"% ,4    " !].FU74U#1B-T+  ")+0  &               @ &V
M2@  86)O<RTR,#(S,3$Q,WAE>'@Y.3(N:'1M4$L%!@     &  8 D $  ,E6
$      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
